Abstract:366 Background: There is a paucity of data with respect to optimal management of metastatic renal cell carcinoma (mRCC) in older adults. Real world data may help close this knowledge gap and improve care for older patients with mRCC. Methods: The Canadian Kidney Cancer information system (CKCis) was utilized to identify patients with mRCC, categorizing them as either older (defined as age ≥75 years) or younger (age <75 years). We compared first line (1L) mRCC management strategies and treatment-related toxicities. Secondary outcomes were overall survival (OS) and time to treatment discontinuation (TTD). Chi-Square and Fisher’s Exact tests were used to compare groups, and survival outcomes were measured by Kaplan-Meier method. Cox’s proportional hazard ratio (HR) were reported by age adjusting for IMDC risk groups, histology, and Charlson Comorbidity Index (CCI) for OS and TTD. Results: 2576 patients were included (n=2203 <75 years old; n=373 ≥75 years old). Baseline demographics were comparable between groups, though older patients had more comorbidities (5+, 95% vs. 67%, p<0.0001) and more frequently had Karnofsky Performance Status <70% (18% vs. 13%, p=0.01). Older patients underwent metastasectomy less frequently (15% vs. 25%, p=0.0001) and were less likely to be enrolled in clinical trials (10% vs. 24%, p<0.0001). Older patients received 1L tyrosine kinase inhibitor (TKI) monotherapy more frequently (79% vs. 69%, p<0.0001) than immune checkpoint inhibitor (ICI)-based treatment, even when adjusted by year to account for changes in practice patterns in the post-ICI era (65% vs. 44%, p<0.0001). Amongst all patients, the TKI monotherapy most frequently prescribed was sunitinib, though older patients were more likely to receive pazopanib than younger patients ( p<0.0001). Amongst all patients who received 1L ICI-based treatment, there was no difference in the type of ICI regimen (i.e. doublet ICI versus ICI plus TKI) prescribed when compared by age ( p=0.61). Older patients did not experience more frequent treatment-related toxicities with ICI-based treatment. They did however experience more grade 3+ toxicity with TKI monotherapy. Older patients had shorter OS even when controlling for IMDC score, CCI and histology (HR 1.21, 95% CI 1.03-1.43, p=0.02). There was no difference in TTD by groups. Conclusions: Patients ≥75 years of age received TKI monotherapy more frequently than those <75 years of age, though when they received ICI-based regimens, they did not experience more treatment-related toxicities nor more dose modifications. Clinicians should individualize treatments for older patients not solely based on age, but after discussion of all available options in a patient-centered manner, considering comorbidities, disease burden, and patient preferences.

Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma

Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study

Immunosenescence and immunotherapy in older NSCLC patients

Immune Checkpoint Inhibitors in Geriatric Oncology

Real-World Prevalence and Tolerability of Immune-Related Adverse Events in Older Adults with Non-Small Cell Lung Cancer: A Multi-Institutional Retrospective Study

Real-world Data on the First-Line Immune Checkpoint Inhibitors or in Combination with Chemotherapy in Older Patients (aged ≥ 75 Years) with Advanced Non-Small Cell Lung Cancer

Inclusion, characteristics, and reporting of older adults in FDA registration studies of immunotherapy, 2018-2022

Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients

Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study

Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients

The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer

Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases

Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials

Age-related efficacy of immunotherapies in advanced non-small cell lung cancer: a comprehensive meta-analysis

Real-world practice patterns, treatment-related toxicity, and survival outcomes in older patients with metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).

Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer

The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC

Associations between age and patient‐reported outcomes, emergency department visits, and hospitalizations among lung cancer patients receiving immune checkpoint inhibitors

Geriatric predictors of response and adverse events in older patients with cancer treated with immune checkpoint inhibitors: A systematic review

Toxicity profile of camrelizumab-based immunotherapy in older adults with advanced cancer

Comparison of Immune Checkpoint Inhibitors Between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis.